3:30 PM
Oct 11, 2017
 |  BC Extra  |  Company News

FDA reviewers concur with Aerie on Rhopressa's efficacy

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) gained $8.95 (16%) to $64.30 on Wednesday after FDA released briefing documents ahead of an advisory committee meeting to discuss an NDA for Rhopressa netarsudil 0.02%. Reviewers said they concurred with Aerie's "'overall efficacy conclusion" that Rhopressa reduces elevated intraocular pressure (IOP) in patients...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >